Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.47 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197857 | 0.81 | KDM5A (0.54) | JAK2TYK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL13165570 | 0.79 | TYK2 (0.66) | JAK2TYK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL7672757 | 0.79 | SMARCA2 (0.63) | JAK2TYK2ALDH1A1TDP1KDM4E | |
| SCHEMBL5520229 | 0.79 | KDM4E (0.49) | JAK2TYK2ALDH1A1TDP1KDM4E | |
| SCHEMBL14168412 | 0.79 | ALDH1A1 (0.52) | JAK2TYK2ALDH1A1TDP1KDM4E | |
| SCHEMBL3244565 | 0.78 | AR (0.56) | JAK2TYK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL9687074 | 0.78 | TYK2 (0.49) | JAK2TYK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL21212495 | 0.78 | KDM4E (0.47) | JAK2TYK2ALDH1A1TDP1KDM4E | |
| SCHEMBL16305244 | 0.78 | KDM4E (0.47) | JAK2TYK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL7672749 | 0.78 | KDM4E (0.47) | JAK2TYK2ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | GSK3B, GSK3A, GYS2 | JAK2 1468/4885TYK2 249/4885ALDH1A1 3930/4885 |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | GGPS1, HMGCR, COASY | JAK2 4040/4885TYK2 2865/4885ALDH1A1 2767/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | JAK2 4039/4885TYK2 2874/4885ALDH1A1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.